Alector (ALEC) Current Deferred Revenue (2018 - 2026)
Alector (ALEC) posted quarterly Current Deferred Revenue of $6.7 million for Q1 2026, down 69.23% year-over-year from $21.8 million in Q1 2025, and up 0.58% quarter-over-quarter from $6.7 million in Q4 2025.
Alector (ALEC) Current Deferred Revenue (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Current Deferred Revenue for 9 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 69.23% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (down 69.23% YoY), while the FY2025 annual figure was $6.7 million, down 71.75% from the prior year.
- Current Deferred Revenue rose to $6.7 million in Q1 2026 per ALEC's latest filing, from $6.7 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $444.9 million in Q1 2022 and bottomed at $454800.0 in Q3 2022.
- Historically, Current Deferred Revenue has averaged $90.8 million across 5 years, with a median of $55.4 million in 2024.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue plunged 99.52% — and 2023, when it surged 17613.5%.
- Alector's Current Deferred Revenue stood at $48.2 million in 2022, then jumped by 72.04% to $83.0 million in 2023, then plunged by 71.48% to $23.7 million in 2024, then plunged by 71.75% to $6.7 million in 2025, then rose by 0.58% to $6.7 million in 2026.
- Business Quant data shows ALEC's Current Deferred Revenue at $6.7 million in Q1 2026, $6.7 million in Q4 2025, and $11.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Alector | 218.85 Mn | 46.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.72 Mn |
| Dec 31, 2025 | 6.68 Mn |
| Sep 30, 2025 | 11.74 Mn |
| Jun 30, 2025 | 13.40 Mn |
| Mar 31, 2025 | 21.85 Mn |
| Dec 31, 2024 | 23.66 Mn |
| Sep 30, 2024 | 55.43 Mn |
| Jun 30, 2024 | 63.96 Mn |
| Mar 31, 2024 | 73.35 Mn |
| Dec 31, 2023 | 82.98 Mn |
| Sep 30, 2023 | 80.56 Mn |
| Jun 30, 2023 | 68.55 Mn |
| Mar 31, 2023 | 433.60 Mn |
| Dec 31, 2022 | 48.23 Mn |
| Sep 30, 2022 | 454,800.00 |
| Jun 30, 2022 | 106.99 Mn |
| Mar 31, 2022 | 444.90 Mn |
| Dec 31, 2021 | 90.80 Mn |
| Sep 30, 2021 | 94.68 Mn |
| Jun 30, 2021 | 25.42 Mn |